Oncogene-addicted NSCLC highlights from ELCC 2026

Prof. Nicolas Girard joined us at the European Lung Cancer Congress, ELCC 2026, to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

Prof. Girard reviewed data from the following studies: 

• Beamion LUNG-1: Zongertinib in treatment-naȉve patients with HER2-mutant NSCLC, including those with active brain metastases. Heymach J, et al. Abstract 6MO, ELCC 2026
• SOHO-01: Characterisation and management of sevabertinib-induced diarrhea. Girard N, et al. Abstract 18P, ELCC 2026
• IELCART: Clinical outcomes in patients with early-stage HER2-mutated NSCLC: A prospective cohort study.
  Gros L, et al. Abstract 239P, ELCC 2026
• OptiTROP-Lung03: Sacituzumab tirumotecan in patients with previously treated advanced EGFR-mutated NSCLC: Final OS analysis from the randomised study. Yang Y, et al. Abstract LBA4, ELCC 2026

Watch his short summary video today and read the key clinical takeaways here.   Rembember, you can also download the accompanying slides for a more detailed update!

Clinical Takeaways 

• Beamion-Lung1: Zongertinib shows practice-changing potential as a first-line targeted therapy in HER2-mutant NSCLC, with high systemic response rates, durable disease control, and clinically meaningful CNS activity, including responses in patients with untreated or active brain metastases, alongside a manageable safety profile 

• SOHO-01: Diarrhea with sevabertinib is predictable and manageable with proactive measures, meaning patients can stay on treatment longer without compromising dose intensity 

• IELCART: In patients with resected stage IA NSCLC, HER2 mutations occur at a similar frequency to advanced disease but in early-stage disease there was no clear impact on outcomes, suggesting these alterations do not currently inform prognosis or adjuvant treatment decisions 

• OptiTROP-Lung03: Sacituzumab tirumotecan demonstrates a clinically meaningful overall survival benefit over docetaxel in previously treated EGFR-mutant NSCLC, supporting its use as a preferred post-TKI treatment option and reinforcing the growing role of ADCs in this setting